Online citations, reference lists, and bibliographies.

Bioreactor Process Parameter Screening Utilizing A Plackett-Burman Design For A Model Monoclonal Antibody.

C. Agarabi, John E. Schiel, S. Lute, Brittany Chavez, M. Boyne, K. Brorson, M. Khan, E. Read
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Consistent high-quality antibody yield is a key goal for cell culture bioprocessing. This endpoint is typically achieved in commercial settings through product and process engineering of bioreactor parameters during development. When the process is complex and not optimized, small changes in composition and control may yield a finished product of less desirable quality. Therefore, changes proposed to currently validated processes usually require justification and are reported to the US FDA for approval. Recently, design-of-experiments-based approaches have been explored to rapidly and efficiently achieve this goal of optimized yield with a better understanding of product and process variables that affect a product's critical quality attributes. Here, we present a laboratory-scale model culture where we apply a Plackett-Burman screening design to parallel cultures to study the main effects of 11 process variables. This exercise allowed us to determine the relative importance of these variables and identify the most important factors to be further optimized in order to control both desirable and undesirable glycan profiles. We found engineering changes relating to culture temperature and nonessential amino acid supplementation significantly impacted glycan profiles associated with fucosylation, β-galactosylation, and sialylation. All of these are important for monoclonal antibody product quality.
This paper references
10.1093/biomet/33.4.305
THE DESIGN OF OPTIMUM MULTIFACTORIAL EXPERIMENTS
R. Plackett (1946)
10.1002/BIT.10116
Chemometric evaluation of on‐line high‐pressure liquid chromatography in mammalian cell cultures: Analysis of amino acids and glucose
Tina M. Larson (2002)
10.1016/j.jpba.2012.01.002
Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate.
David Awotwe-Otoo (2012)
10.1038/nbt0109-26
Quality by design for biopharmaceuticals
A. Rathore (2009)
10.1002/BIT.20897
Application of a continuous bioreactor cascade to study the effect of linoleic acid on hybridoma cell physiology
D. Kisztelinski (2006)
10.1002/btpr.1605
Genomic analysis of a hybridoma batch cell culture metabolic status in a standard laboratory 5 L bioreactor
Bhargavi Kondragunta (2012)
10.1002/9780470054581.EIB170
Quality by Design (QbD), Biopharmaceutical Manufacture
Rakhi B. Shah (2010)
10.1002/bit.22348
Identification of cell culture conditions to control N‐glycosylation site‐occupancy of recombinant glycoproteins expressed in CHO cells
M. Gawlitzek (2009)
The effect of fatty acids on hybridoma cell growth and antibody productivity in serum-free cultures. Journal of biotechnology
M Butler (1995)
On the evaluation of gasliquid interfacial effects on hybridoma viability in bubble column bioreactors. Developments in biological standardization
A Handa (1987)
10.1016/J.JMB.2007.02.034
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
S. Matsumiya (2007)
10.1007/s00216-012-5749-5
LC-MS/MS biopharmaceutical glycoanalysis: identification of desirable reference material characteristics
John E. Schiel (2012)
10.1016/0141-0229(91)90108-M
Biological responses of hybridoma cells to hydrodynamic shear in an agitated bioreactor.
I. Abu-Reesh (1991)
10.1002/bit.23218
Controlling glycation of recombinant antibody in fed‐batch cell cultures
Inn H Yuk (2011)
Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design
GM Lee (1999)
Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures.
Danny Chee Furng Wong (2005)
Successful transfer and 200fold scale-up of a r-CHO cell fed-batch process using a new cGMP compliant basal and feed medium combination
J Mitschelen (2008)
10.1002/BIT.21013
Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo‐Fc expressing CHO cells cultivated in controlled batch bioreactors
Evelyn Trummer (2006)
10.1002/btpr.1728
Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture
E. Read (2013)
10.1158/1078-0432.CCR-06-1335
A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients
E. Suzuki (2007)
10.1016/B978-0-08-088504-9.00156-2
Integrating Process Scouting Devices (PSDs) With Bench-Scale Devices: Challenges and Opportunities for Mammalian Cell Culture
José R Vallejos (2011)
10.1002/btpr.392
Advances in clone selection using high‐throughput bioreactors
Bhargavi Kondragunta (2010)
10.1021/bp049825t
Temperature Reduction in Cultures of hGM‐CSF‐expressing CHO Cells: Effect on Productivity and Product Quality
Mariela Bollati-Fogolín (2005)
10.1016/0922-338X(92)90034-R
Effect of Dissolved Oxygen Concentration on Monoclonal Antibody Production in Hybridoma Cell Cultures
T. Ogawa (1992)
10.1016/j.ijpharm.2011.11.036
A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale.
Xiaoming Xu (2012)
10.1016/S1389-1723(04)70198-X
Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture.
Zhaolie Chen (2004)
10.1016/0161-5890(95)00118-2
The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H.
P. Boyd (1995)
NIST/SEMATECH e-Handbook of Statistical Methods
W. Guthrie (2005)
10.1016/0168-1656(95)00017-K
The effect of fatty acids on hybridoma cell growth and antibody productivity in serum-free cultures.
M. Butler (1995)
10.1002/bit.22764
Defining process design space for monoclonal antibody cell culture
S. Abu-Absi (2010)
10.1016/J.MOLIMM.2007.02.005
Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
K. Masuda (2007)
10.1074/jbc.M604221200
System-wide Genomic and Biochemical Comparisons of Sialic Acid Biology Among Primates and Rodents
T. K. Altheide (2006)
10.1002/bab.1151
Evaluation of butyrate‐induced production of a mannose‐6‐phosphorylated therapeutic enzyme using parallel bioreactors
Chikkathur N. Madhavarao (2014)
Designing in quality: Approaches to defining the design space for a monoclonal antibody process
A Banerjee (2010)
Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.
L. Rubinstein (1988)
10.1074/jbc.M110.204362
In Vivo Crystallization of Human IgG in the Endoplasmic Reticulum of Engineered Chinese Hamster Ovary (CHO) Cells
H. Hasegawa (2011)
10.1042/bj3220615
Unsaturated fatty acids enhance cell yields and perturb the energy metabolism of an antibody-secreting hybridoma.
M. Butler (1997)
10.1007/s00216-014-8108-x
Post-translational structural modifications of immunoglobulin G and their effect on biological activity
Laura K Hmiel (2014)
10.1016/S0168-1656(99)00004-8
Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design.
G. Lee (1999)
10.1016/j.ijpharm.2009.12.040
Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
Z. Rahman (2010)
10.1002/bit.24602
Automated dynamic fed‐batch process and media optimization for high productivity cell culture process development
Franklin Lu (2013)
10.1002/bab.35
Industry and regulatory experience of the glycosylation of monoclonal antibodies
E. Read (2011)
On the evaluation of gas-liquid interfacial effects on hybridoma viability in bubble column bioreactors.
A. Handa (1987)
10.1074/jbc.M210665200
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*
T. Shinkawa (2003)
10.1021/bp050228w
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Jason Hodoniczky (2005)
10.1002/btpr.1530
Effect of hydrocortisone on the production and glycosylation of an Fc‐fusion protein in CHO cell cultures
Yolande Rouiller (2012)
10.1533/9780857099785.234
8 – Two-level Fractional Factorial Designs
William P. Gardiner (1998)
10.1016/J.BEJ.2005.04.009
Kinetic analysis of hybridoma cell culture in a protein-free medium: Substrate and agitation effects
L. Legazpi (2005)
10.1002/BIT.10013
Glucose-based optimization of CHO-cell perfusion cultures.
J. E. Dowd (2001)
10.1002/BIT.10566
Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells.
S. K. Yoon (2003)
10.1146/annurev.bi.54.070185.003215
Assembly of asparagine-linked oligosaccharides.
R. Kornfeld (1985)



This paper is referenced by
10.1177/2168479014567323
How the Critical Path Initiative Addresses CDER’s Regulatory Science Needs
M. Geanacopoulos (2015)
10.1208/s12249-018-1032-1
Optimization of a Coupling Process for Insulin Degludec According to a Quality by Design (QbD) Paradigm
Lei Nie (2018)
10.18725/OPARU-4249
Protein aggregation during bioprocessing of monoclonal antibodies in mammalian cell culture
Albert Paúl (2017)
10.1016/j.ijpharm.2016.10.038
Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
Adam C. Fisher (2016)
10.13016/M2OAM8-MSE7
Development of Glycoanalytical Methods for Characterization of Biosimilar Monoclonal Antibodies
Katharina Yandrofski (2018)
10.1002/btpr.2903
Multivariate data analysis of growth medium trends affecting antibody glycosylation
D. N. Powers (2019)
10.3390/PR7040227
Prediction of N-linked Glycoform Profiles of Monoclonal Antibody with Extracellular Metabolites and Two-Step Intracellular Models
S. Sha (2019)
10.1186/S12934-015-0320-7
Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs
A. Marco (2015)
10.1186/s12934-015-0320-7
Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs
A. de Marco (2015)
10.7282/T3736VD9
Simulation-based process analysis and optimization for continuous pharmaceutical manufacturing
Z. Wang (2018)
10.1080/19420862.2018.1486355
Heterologous recombinant expression of non-originator NISTmAb
Lila Kashi (2018)
10.1016/j.dib.2016.10.003
Hybridoma cell-culture and glycan profile dataset at various bioreactor conditions
Hemlata Bhatia (2016)
10.1002/bit.26534
Identification of process conditions influencing protein aggregation in Chinese hamster ovary cell culture
A. Paul (2018)
10.1002/bit.26383
Opportunities and challenges of real‐time release testing in biopharmaceutical manufacturing
Mo Jiang (2017)
10.1371/journal.pone.0210712
Therapeutic Fc fusion protein misfolding: A three-phasic cultivation experimental design
Atefeh Ghorbani Aghdam (2019)
10.1016/j.sbi.2016.08.007
Metabolic flux control in glycosylation.
Andrew G. McDonald (2016)
10.1007/S13749-015-0032-Y
Red pigment production by Monascus purpureus using sweet potato-based medium in submerged fermentation
P. Srivastav (2015)
10.1002/btpr.2575
Impact of media and antifoam selection on monoclonal antibody production and quality using a high throughput micro‐bioreactor system
Sai Rashmika Velugula-Yellela (2018)
10.1155/2016/2074149
Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations
Brittany Chavez (2016)
10.3791/58947
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System.
Sai Rashmika Velugula-Yellela (2019)
10.1016/j.tibtech.2016.02.013
N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.
S. Sha (2016)
10.1002/btpr.2894
Real‐time quantification and supplementation of bioreactor amino acids to prolong culture time and maintain antibody product quality
D. N. Powers (2019)
10.5731/pdajpst.2016.007054
Mycoplasma Clearance and Risk Analysis in a Model Bioprocess
J. Wang (2017)
10.1007/s00449-016-1693-7
Investigation of the interactions of critical scale-up parameters (pH, pO2 and pCO2) on CHO batch performance and critical quality attributes
Matthias Brunner (2016)
10.1007/978-1-4939-6972-2_14
Engineer Medium and Feed for Modulating N-Glycosylation of Recombinant Protein Production in CHO Cell Culture.
Yuzhou Fan (2017)
10.11648/j.ijpc.20180402.11
Impact Factors in the Process Development for Therapeutic Antibodies
Xiaopei Cui (2018)
10.1016/j.ijpharm.2016.08.046
A design space exploration for control of Critical Quality Attributes of mAb.
Hemlata Bhatia (2016)
10.1002/btpr.2402
Exploring the linkage between cell culture process parameters and downstream processing utilizing a plackett‐burman design for a model monoclonal antibody
C. Agarabi (2017)
10.1016/B978-0-444-63663-8.00016-1
Advanced Process and Control Strategies for Bioreactors
R. Pörtner (2017)
10.1002/elsc.201800168
A statistical approach to improve compound screening in cell culture media
E. Puente-Massaguer (2019)
Semantic Scholar Logo Some data provided by SemanticScholar